IP Library Granted Patent US 11,007,247
Granted Patent B2
US 11,007,247 · App. 15/038,068 · Granted May 18, 2021

Compositions and methods for delivery of bioencapsulated proteins across blood-brain and retinal barriers

Inventor: Henry Daniell (Media, PA)
Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
A61K38/1709A61K9/0053A61K9/19A61K9/5068A61K38/164A61K38/17A61K47/6415A61K47/6811C07K14/28C07K14/4713C12N15/8257C07K2319/00C07K2319/55Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,007,247
App. No.
15/038,068
Granted
May 18, 2021
Kind
B2
Abstract

Compositions and methods effective to provide therapeutic benefit for disorders of the central nervous system via oral or systemic delivery of therapeutic proteins produced in plastids are disclosed.

Claims (9)

1. A method for delivery of human myelin basic protein (MBP) across the blood brain barrier and blood retinal barrier in a subject in need thereof, said subject having a central nervous system disorder, comprising:

a) administering to the subject a composition comprising lyophilized leaf material containing an effective amount of a fusion protein comprising said MBP operably linked to cholera toxin B (CTB) subunit in a 1:1 ratio under conditions whereby said fusion protein crosses the blood brain and blood retinal barrier and wherein said composition is administered orally and effective to

i) reduce levels of amyloid beta protein in the brain; and/or

ii) reduce amyloid levels in the retina; and/or

iii) prevent loss of retinal ganglion cells; and/or

iv) decrease the ratio of insoluble vs soluble amyloid beta protein42 in hippocampus;

said CTB-MBP fusion protein being present in a plastid transformed with a stable plastid transformation vector and expression vector which expresses said CTB-MBP fusion protein in said leaf material, wherein said CTB and human MBP are separated by a glycine-proline-glycine-proline hinge region and a furin site,

wherein the subject is assessed for the reduction of amyloid plaque levels.

2. The method of claim 1 , wherein said subject is a human or nonhuman mammal.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2020
From: DANIELL, HENRY
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 051875/0501 →
CONFIRMATORY LICENSE Recorded Nov 24, 2017
From: UNIVERSITY OF PENNSYLVANIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044510/0508 →
Continuity (2)
Provisional Application 61907368 · Nov 21, 2013
Related Publication 20160367629A1 · Dec 22, 2016